DaVita (NYSE:DVA) Stock Jumps 3.7% - Time to Buy?

DaVita logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • DaVita shares rose 3.7% to about $162.20, though trading volume was 65% below the average session volume.
  • Analysts have a Moderate Buy consensus, with four Buy and three Hold ratings and an average price target of $235.86.
  • DaVita beat quarterly expectations, reporting EPS of $3.82 versus $3.57 expected and revenue of $3.58 billion; revenue increased 4.6% year over year.
  • Five stocks to consider instead of DaVita.

DaVita Inc. (NYSE:DVA - Get Free Report)'s stock price was up 3.7% during trading on Friday. The company traded as high as $162.99 and last traded at $162.1960. Approximately 311,386 shares traded hands during mid-day trading, a decline of 65% from the average session volume of 888,047 shares. The stock had previously closed at $156.34.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on DVA shares. Raymond James Financial set a $220.00 price objective on shares of DaVita in a research note on Friday, August 7th. Weiss Ratings upgraded shares of DaVita from a "hold (c+)" rating to a "buy (b-)" rating in a report on Friday, October 9th. Barclays cut their target price on shares of DaVita from $224.00 to $216.00 and set an "equal weight" rating for the company in a research report on Monday, November 2nd. Oppenheimer set a $220.00 price target on shares of DaVita in a report on Friday, August 7th. Finally, UBS Group raised their price target on DaVita from $270.00 to $287.00 and gave the company a "buy" rating in a research report on Monday, November 2nd. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $235.86.

View Our Latest Stock Analysis on DVA

DaVita Stock Up 3.3%

The company has a market capitalization of $10.16 billion, a P/E ratio of 11.89, a PEG ratio of 0.41 and a beta of 0.87. The firm has a 50-day moving average price of $181.31 and a two-hundred day moving average price of $181.57.

DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Thursday, October 29th. The company reported $3.82 EPS for the quarter, beating the consensus estimate of $3.57 by $0.25. The firm had revenue of $3.58 billion during the quarter, compared to analysts' expectations of $3.52 billion. DaVita had a net margin of 6.49% and a negative return on equity of 225.93%. The business's quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the company earned $2.51 EPS. On average, analysts predict that DaVita Inc. will post 14.66 EPS for the current fiscal year.

Institutional Investors Weigh In On DaVita

Institutional investors have recently added to or reduced their stakes in the company. Advisors Asset Management Inc. acquired a new stake in shares of DaVita during the 3rd quarter worth approximately $425,000. Heartland Bank & Trust Co lifted its position in DaVita by 4.4% in the third quarter. Heartland Bank & Trust Co now owns 2,350 shares of the company's stock worth $411,000 after purchasing an additional 98 shares during the period. Innovator Capital Management LLC bought a new position in DaVita in the third quarter worth $328,000. Coastal Bridge Advisors LLC acquired a new stake in DaVita during the third quarter worth $312,000. Finally, Allworth Financial LP boosted its stake in DaVita by 61.5% during the third quarter. Allworth Financial LP now owns 2,589 shares of the company's stock worth $453,000 after buying an additional 986 shares in the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

About DaVita

(Get Free Report)

DaVita Inc. is a healthcare provider focused on kidney care. Its core business is operating outpatient dialysis centers that provide treatment and related services to people with chronic kidney failure. The company also offers home dialysis programs, provides dialysis services to patients in hospitals, and supports kidney care through services such as care coordination and education. DaVita primarily serves patients in the United States and also operates in international markets. Founded in 1994 as Total Renal Care, the company adopted the name DaVita in 2000.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in DaVita Right Now?

Before you consider DaVita, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.

While DaVita currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines